Business Description
Bio-Rad Laboratories Inc
NAICS : 334516
SIC : 3826
ISIN : US0905722072
Share Class Description:
STU:BUWA: Class ADescription
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.17 | |||||
| Equity-to-Asset | 0.71 | |||||
| Debt-to-Equity | 0.19 | |||||
| Debt-to-EBITDA | -1.72 | |||||
| Interest Coverage | 6.23 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 3.09 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 2.7 | |||||
| 3-Year EPS without NRI Growth Rate | 3.5 | |||||
| 3-Year FCF Growth Rate | -22.1 | |||||
| 3-Year Book Growth Rate | -2.5 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.59 | |||||
| 9-Day RSI | 50.51 | |||||
| 14-Day RSI | 49.32 | |||||
| 6-1 Month Momentum % | 23.99 | |||||
| 12-1 Month Momentum % | 11.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.14 | |||||
| Quick Ratio | 4.52 | |||||
| Cash Ratio | 3.26 | |||||
| Days Inventory | 244.87 | |||||
| Days Sales Outstanding | 65.03 | |||||
| Days Payable | 37.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 1.5 | |||||
| Shareholder Yield % | 4.29 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 54.39 | |||||
| Operating Margin % | 11.86 | |||||
| Net Margin % | -30.18 | |||||
| FCF Margin % | 8.64 | |||||
| ROE % | -9.62 | |||||
| ROA % | -6.82 | |||||
| ROIC % | 2.51 | |||||
| ROC (Joel Greenblatt) % | -57.09 | |||||
| ROCE % | -8.76 | |||||
| Years of Profitability over Past 10-Year | 8 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 28.96 | |||||
| PE Ratio without NRI | 31.48 | |||||
| Shiller PE Ratio | 14.9 | |||||
| PS Ratio | 3.65 | |||||
| PB Ratio | 1.24 | |||||
| Price-to-Tangible-Book | 1.37 | |||||
| Price-to-Free-Cash-Flow | 41.84 | |||||
| Price-to-Operating-Cash-Flow | 22.75 | |||||
| EV-to-EBIT | -9.42 | |||||
| EV-to-Forward-EBIT | 23.31 | |||||
| EV-to-EBITDA | -11.16 | |||||
| EV-to-Forward-EBITDA | 17.37 | |||||
| EV-to-Revenue | 3.49 | |||||
| EV-to-Forward-Revenue | 3.38 | |||||
| EV-to-FCF | 40.24 | |||||
| Price-to-Projected-FCF | 1.03 | |||||
| Price-to-Median-PS-Value | 0.95 | |||||
| Price-to-Graham-Number | 1.38 | |||||
| Earnings Yield (Greenblatt) % | -10.62 | |||||
| FCF Yield % | 2.42 | |||||
| Forward Rate of Return (Yacktman) % | 22.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bio-Rad Laboratories Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,365.15 | ||
| EPS (TTM) (€) | -26.311 | ||
| Beta | 1.4 | ||
| Volatility % | 35.16 | ||
| 14-Day RSI | 49.32 | ||
| 14-Day ATR (€) | 4.635523 | ||
| 20-Day SMA (€) | 315.265 | ||
| 12-1 Month Momentum % | 11.56 | ||
| 52-Week Range (€) | 242.7 - 352 | ||
| Shares Outstanding (Mil) | 28 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bio-Rad Laboratories Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bio-Rad Laboratories Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Bio-Rad Laboratories Inc Frequently Asked Questions
What is Bio-Rad Laboratories Inc(STU:BUWA)'s stock price today?
The current price of STU:BUWA is €314.10. The 52 week high of STU:BUWA is €352.00 and 52 week low is €242.70.
When is next earnings date of Bio-Rad Laboratories Inc(STU:BUWA)?
The next earnings date of Bio-Rad Laboratories Inc(STU:BUWA) is 2025-02-14 Est..
Does Bio-Rad Laboratories Inc(STU:BUWA) pay dividends? If so, how much?
Bio-Rad Laboratories Inc(STU:BUWA) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers